MedTrace Logo

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

NCT04868604 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-05-06

No results posted yet for this study

Summary

The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.

Conditions

  • Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG

64Cu-SAR-bisPSMA

64Cu-SAR-bisPSMA

DRUG

67Cu-SAR-bisPSMA

67Cu-SAR-bisPSMA

Sponsors & Collaborators

  • Clarity Pharmaceuticals Ltd

    lead INDUSTRY

Principal Investigators

  • Clarity Pharmaceuticals · Clarity Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-11
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04868604 on ClinicalTrials.gov